Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
| Revenue (TTM) | $2.38B |
| Gross Profit (TTM) | $2.29B |
| EBITDA | $985.84M |
| Operating Margin | 41.10% |
| Return on Equity | 41.00% |
| Return on Assets | 22.00% |
| Revenue/Share (TTM) | $8.91 |
| Book Value | $7.63 |
| Price-to-Book | 7.25 |
| Price-to-Sales (TTM) | 5.94 |
| EV/Revenue | 5.66 |
| EV/EBITDA | 13.63 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 10.00% |
| Shares Outstanding | $251.35M |
| Float | $204.47M |
| % Insiders | 1.82% |
| % Institutions | 106.72% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
